Clinical trials: Throat Carcinoma
Nasopharyngeal Carcinoma
Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma
This study is a randomized, placebo-controlled, double-blind, multicenter phase III clinical study. Target population is patients with recurrent/metastatic nasopharyngeal carcinoma who had not received systemic chemotherapy.
- Trial name
- NCT03707509
- Testing
- Camrelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Effects of Chemotherapy, Stage IVC Nasopharyngeal Carcinoma
Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma
The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT01915134
- Testing
- Recombinant Human Endostatin plus gemcitabine and cisplatin, Gemcitabine and cisplatin
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients
The investigators have demonstrated the crucial role of the liver-lung axis in the distant metastasis of NPC. Furthermore, the investigators have identified a potential therapeutic approach to improve outcomes in NPC patients by…
- Trial name
- NCT06442709
- Testing
- Tocilizumab Asprin
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Hospital of Nantong University
Nasopharyngeal Carcinoma
Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma
The aim of the study is to assess if gemcitabine in combination with carboplatin as 1st line chemotherapy in patients with metastatic or recurrent nasopharyngeal carcinoma has reasonable efficacy and a favourable toxicity profile…
- Trial name
- NCT00697905
- Testing
- Gemcitabine, Carboplatin, Cisplatin
- Where
- 11 sites in Malaysia
- Volunteers
- 18 people
- Sponsor
- Ministry of Health, Malaysia
Nasopharyngeal Carcinoma, Recurrent or Metastatic
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST…
- Trial name
- NCT03848286
- Testing
- KL-A167 Injection
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Nasopharyngeal Carcinoma
Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients
The purpose of this study is to evaluate whether dietary nitrate supplementation could improve the salivary flow for nasopharyngeal carcinoma patients receiving concurrent chemo-radiation therapy.
- Trial name
- NCT02854410
- Testing
- Sodium nitrate, sodium chloride
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Capital Medical University
Head and Neck Neoplasms
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell…
- Trial name
- NCT01087970
- Testing
- Pemetrexed, Cetuximab, Carboplatin
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
This phase I trial tests the safety, side effects, and best dose of camonsertib in combination with stereotactic body radiation therapy in controlling disease in patients with head and neck squamous cell cancer that has come back…
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
- Trial name
- NCT07156227
- Testing
- Biospecimen Collection, Camonsertib, Computed Tomography
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Nasopharyngeal Carcinoma
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma
The purpose of this study is to determine whether an EBV-LMP1 targeted DNAzyme is effective in radiosensitization of nasopharyngeal carcinoma in combination with standard radiation therapy.
- Trial name
- NPC-DZ (NCT01449942)
- Testing
- DNAzyme targeting EBV-LMP1 (DZ1), Saline
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xiangya Hospital of Central South University
Nasopharyngeal Carcinoma (NPC), CTIT-Chemotherapy Induced Thrombocytopenia
A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma
This study is a single-arm, exploratory, self-controlled clinical trial for the prevention of thrombocytopenia induced by gemcitabine plus cisplatin in the treatment of nasopharyngeal carcinoma.
- Trial name
- NCT07252375
- Testing
- herombopag olamine tablets
- Volunteers
- 35 people
- Sponsor
- Fujian Cancer Hospital
Oral Cancer, Laryngeal Cancer
The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis
The purpose of this study is to investigate the role of lymphangiogenesis in the metastasis of head and neck cancer.
- Conditions
- Oral Cancer, Laryngeal Cancer, Hypopharyngeal Cancer
- Trial name
- NCT00173381
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Nasopharyngeal Carcinoma
Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Several prospective randomized trials have demonstrated that concurrent chemoradiotherapy was superior to radiotherapy alone in the treatment of locoregionally advanced nasopharyngeal carcinoma (NPC).
- Trial name
- NCT02434614
- Testing
- Docetaxel,Cisplatin,Fluorouracil, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 6 sites in China
- Volunteers
- 440 people
- Sponsor
- Wei Jiang
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
This phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy…
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT07195734
- Testing
- Biospecimen Collection, Carboplatin, Cemiplimab
- Where
- 115 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Cancer Institute (NCI)
Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal
Concordance of Two Endoscopic Procedures for Diagnosis of Carcinoma of the Upper Aerodigestive Tract
This study will compare TNFE-NBI and biopsy, with DRE and biopsy for the diagnostic evaluation and staging of patients with suspicious UADT lesions.
- Conditions
- Upper Aerodigestive Tract Lesions, Neoplasms, Oropharyngeal, Oropharyngeal Cancer, Neoplasms, Hypopharyngeal
- Trial name
- TNFE-NBI (NCT01175499)
- Testing
- Direct Rigid Endoscopy, Transnasal Flexible Endoscopy with Narrowband Imaging
- Sponsor
- University of California, San Francisco
Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma
pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer
This phase II trial tests how well pB1-11 and human papillomavirus tumor antigen (TA-HPV) vaccines in combination with pembrolizumab work in treating patients with oropharyngeal cancer that has come back (recurrent) or that has…
- Trial name
- NCT05799144
- Testing
- DNA Vaccine, Human Papillomavirus Tumor Antigen Vaccine, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Michael K. Gibson
Circulating Tumor Cell, Oropharyngeal Cancer
Prospective Study for the Prognostic and Predictive Role of Circulating Tumor Cells in Patients With Oropharyngeal Squamous Cell Carcinoma: CTCO (Circulating Tumor Cells in the Oropharynx)
Head and neck cancers (HNSCC) are primarily squamous cell cancers represented by tumors of the upper aerodigestive tract. Locally advanced stages (stages III and IV) account for 50 to 70% of all presentations.
- Trial name
- CTCO (NCT04696744)
- Testing
- CTC detection
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Hospices Civils de Lyon
Nasopharyngeal Carcinoma
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
The aim of the study was to determine the efficacy and safety of toripalimab combined with radiotherapy in the treatment of oligometastatic nasopharyngeal carcinoma
- Trial name
- NCT05147844
- Testing
- Toripalimab
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Xinqiao Hospital of Chongqing
Nasopharyngeal Carcinoma
Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma
This is the first phase II randomized clinical trial of concurrent chemoradiotherapy with or without EGFR blocker Nimotuzumab for high risk advanced nasopharyngeal carcinoma(NPC) , determining whether concurrent…
- Trial name
- NCT04223024
- Testing
- CCRT+Nimotuzumab, CCRT alone
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma
This randomized clinical trial determining whether Sintilimab plus Capecitabine versus Capecitabine alone can improve the progression-free survival rate of NPC patients with unfavorable response to induction chemotherapy.
- Trial name
- NCT05201859
- Testing
- Sintilimab, Capecitabine
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
The Value of Post-radiation Detectable Plasma EBV DNA in High-risk Nasopharyngeal Carcinoma Patients
An additional blood test at 2-3 months after RT is a valuable biomarker in predicting treatment outcome for NPC patients. Patients with persistently detectable EBV DNA during re-staging survey 2-3 months after RT should…
- Trial name
- NCT03981224
- Volunteers
- 706 people, healthy volunteers welcome
- Sponsor
- Taichung Veterans General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.